EGFR and non-small cell lung carcinoma: In LuxLung 7, afatinib was compared with gefitinib in a phase 2 B, open-label, randomized, controlled trial of EGFR mutation-positive NSCLC in treatment-naive patients and showed significant improvement in progression-free survival (PFS) and time-to-treatment failure.